Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with these defects but failed to adequately address the issues through customer alerts [3]. - The company's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price dropped by 22.4%, closing at $21.76 [4]. - Investors who suffered losses between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for alleged violations of federal securities laws related to the Novum LVP device malfunctions, which posed serious risks to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Baxter securities between February 23, 2023, and July 30, 2025 [2]. - Allegations include that Baxter misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Baxter have until December 15, 2025, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, due to alleged misleading information regarding the safety and efficacy of the Novum LVP product line [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which led to malfunctions that posed serious risks to patients, including underinfusion, overinfusion, and non-delivery of fluids [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [5]. - The lawsuit alleges that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of Baxter International Inc. shareholders who purchased stock between February 23, 2022, and July 30, 2025, alleging that the company misled investors regarding the safety and efficacy of its Novum LVP devices [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP devices, which led to malfunctions and posed serious risks to patients [5]. - Allegations include that Baxter was aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [5]. - The lawsuit asserts that Baxter's statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Participation Information - Shareholders who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6].

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to safety concerns and misleading information regarding its Novum IQ Large Volume Pump, which has been linked to serious patient injuries and deaths [3][4]. Summary by Sections Incident Overview - Safety concerns regarding Baxter's Novum IQ Large Volume Pump emerged on April 7, 2025, following a whistleblower report about inaccurate infusion [3]. - Baxter issued a warning letter on April 24, 2025, acknowledging potential underinfusion risks and disclosing one serious injury [3]. - A second warning letter was sent on July 14, 2025, revealing 79 reports of serious injuries and two patient deaths related to the device [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a share price decline of $6.29, or approximately 22.4%, from $28.05 to $21.76 [3]. Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities from February 23, 2022, to July 30, 2025 [4]. - Allegations include failure to disclose systemic defects in the Novum LVP, which caused malfunctions and exposed patients to serious risks [4]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [4]. - The lawsuit claims that there was a heightened risk of customers removing existing Novum LVPs from service and a complete pause in new sales [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [2][3]. Allegations - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period†). Baxter develops, manufactures, and markets medical products. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen. ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to systemic defects in its Novum IQ Large Volume Pump, which posed serious risks to patients [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter made false or misleading statements regarding the Novum IQ Large Volume Pump, which suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - The company announced on July 31, 2025, a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Points - Baxter International Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to a federal securities class action [1] - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action against Baxter [1] Company Overview - Baxter International Inc. is listed on the NYSE under the ticker symbol BAX [1] - Faruqi & Faruqi, LLP is a national securities law firm with offices in New York, Pennsylvania, California, and Georgia [1]

Core Viewpoint - A securities class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered from systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of all individuals or entities that purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter failed to disclose significant issues with the Novum LVP, including systemic defects that caused malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [2]. Group 2: Implications for Baxter - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might have to halt all new sales of these pumps [2]. - The statements made by Baxter regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 3: Investor Actions - Investors who acquired shares of Baxter are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 15, 2025 [3].